Indaptus Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$19.8M | -$15.4M | -$16.4M | -$14.9M | -$7.7M |
| Operating expenses | $19.8M | $15.4M | $16.4M | $14.9M | $7.7M |
| Cash from operations | -$14.8M | -$12.3M | -$13.4M | -$13.1M | -$11.3M |
| Capital expenditure | — | — | — | — | $3,854 |
| Free cash flow | — | — | — | — | -$11.3M |
| Total assets | $9.3M | $7.3M | $14.9M | $28.1M | $40.6M |
| Total liabilities | — | $3.4M | $2.8M | $3.4M | $4.7M |
Shares outstanding 113.2M · Free float 16.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.